Dr. Ming-Yuan Chen

Co-authors

Following

Followers

Research Focus & Metrics

Explore full metrics on Scilit

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

26 October 2021 in Cancer Communications

Journal Article

The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma

Ling-Long Tang

Yu‐Pei Chen

Chuan‐Ben Chen

Ming-Yuan Chen

Nian‐Yong Chen

Jun Ma

+34

Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the nasopharynx and has a high incidence in Southeast Asia and North Africa. To develop these comprehensive guidelines for the diagnosis and management of NPC, the Chinese Society of Clinical Oncology (CSCO) arranged a multi‐disciplinary team comprising of experts from all sub‐specialties of NPC to write, discuss, and revise the guidelines. Based on the findings of evidence‐based medicine in China and abroad, domestic experts have iteratively developed these guidelines to provide proper management of NPC. Overall, the guidelines describe the screening, clinical and pathological diagnosis, staging and risk assessment, therapies, and follow‐up of NPC, which aim to improve the management of NPC.

1 November 2015 in European Journal of Cancer

Journal Article

Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up

Meng-Xia Zhang

Jing Li

Guo-Ping Shen

Xiong Zou

Jun-Jie Xu

Ming-Yuan Chen

1 April 2017 in European Journal of Cancer

Journal Article

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial

Su-Mei Cao

Qi Yang

Ling Guo

Hai-Qiang Mai

Hao-Yuan Mo

Ming-Huang Hong

+22

17 June 2019 in Nature Genetics

Journal Article

Genome sequencing analysis identifies Epstein–Barr virus subtypes associated with high risk of nasopharyngeal carcinoma

Miao Xu

Youyuan Yao

Hui Chen

Shanshan Zhang

Su-Mei Cao

Jianjun Liu

+25

Epstein–Barr virus (EBV) infection is ubiquitous worldwide and is associated with multiple cancers, including nasopharyngeal carcinoma (NPC). The importance of EBV viral genomic variation in NPC development and its striking epidemic in southern China has been poorly explored. Through large-scale genome sequencing of 270 EBV isolates and two-stage association study of EBV isolates from China, we identify two non-synonymous EBV variants within BALF2 that are strongly associated with the risk of NPC (odds ratio (OR) = 8.69, P = 9.69 × 10⁻²⁵ for SNP 162476_C; OR = 6.14, P = 2.40 × 10⁻³² for SNP 163364_T). The cumulative effects of these variants contribute to 83% of the overall risk of NPC in southern China. Phylogenetic analysis of the risk variants reveals a unique origin in Asia, followed by clonal expansion in NPC-endemic regions. Our results provide novel insights into the NPC endemic in southern China and also enable the identification of high-risk individuals for NPC prevention.

23 July 2020 in JAMA Oncology

Journal Article

Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma

Rui You

You-Ping Liu

Pei-Yu Huang

Xiong Zou

Rui Sun

Ming-Yuan Chen

+26

Nasopharyngeal carcinoma (NPC) has a high prevalence in Southeastern Asia, with age-standardized rates of 22.2 to 27.2 per 100 000 male patients.¹^,2 Incidences of synchronous distant metastasis in endemic NPC range from 6% to 8% at the time of presentation.³^,4 In these patients, gemcitabine and cisplatin (GP) doublet chemotherapy is the standard of care (SOC) as first-line treatment.⁵ Response rates and overall survival (OS) were superior with GP compared with fluorouracil and cisplatin (PF). Median OS of de novo metastatic NPC (mNPC) is approximately 29.1 months with GP.

1 September 2019 in European Journal of Cancer

Journal Article

Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial

Qi Yang

Su-Mei Cao

Ling Guo

Yi-Jun Hua

Pei-Yu Huang

Ming-Yuan Chen

+23

About Me

Prof. Dr. Ming-Yuan Chen, former vice president of the Sun Yat-sen University Nanchang Hospital, deputy director of the Department of Nasopharyngeal Carcinoma, Surgical Center of Nasopharyngeal Carcinoma of Sun Yat-sen University Cancer Center, director of Sun Yat-sen University Cancer Center-The Fifth Affiliated Hospital of Guangzhou Medical University Nasopharyngeal Cancer Surgery Cooperative Ward. He enjoys the honor of National Technology Innovation Leading Talents, New Century Excellent Talents, Outstanding Young Medical Talents in Guangdong Province, etc. He also obtained the title of being the first head-and-neck oncologist in mainland China to be invited to launch courses in the American Academy of Otolaryngology-Head and Neck Surgery. His research interest focuses on comprehensive treatment and molecular mechanisms of nasopharyngeal carcinoma (NPC). As for recurrent NPC, he pioneered the surgical technique of minimally invasive surgery with transnasal endoscopy, providing a new, safe, and effective therapeutic pattern for it. Concerning metastatic nasopharyngeal carcinoma, he led several large-scale phase III clinical trials and established sequential chemoradiotherapy with neoadjuvant chemotherapy as the optimal treatment mode for the prevention and treatment of distant metastasis of NPC, which was successfully selected as one of the 17 major advances in 2021 by ASCO.

Dr. Ming-Yuan Chen

Dr. Ming-Yuan Chen

Research Focus & Metrics

Academic Career Length

Publication Type Breakdown

Representative Publications

About Me